U.S. Markets open in 6 hrs 36 mins
  • S&P Futures

    3,367.75
    -15.25 (-0.45%)
     
  • Dow Futures

    27,224.00
    -141.00 (-0.52%)
     
  • Nasdaq Futures

    11,559.50
    -28.50 (-0.25%)
     
  • Russell 2000 Futures

    1,576.00
    -13.00 (-0.82%)
     
  • Crude Oil

    38.67
    -0.90 (-2.27%)
     
  • Gold

    1,909.10
    -2.80 (-0.15%)
     
  • Silver

    24.58
    +0.01 (+0.06%)
     
  • EUR/USD

    1.1770
    -0.0019 (-0.1648%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    33.35
    +0.89 (+2.74%)
     
  • GBP/USD

    1.3048
    +0.0006 (+0.0496%)
     
  • USD/JPY

    104.2400
    -0.2540 (-0.2431%)
     
  • BTC-USD

    13,750.95
    +40.93 (+0.30%)
     
  • CMC Crypto 200

    271.59
    +10.30 (+3.94%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Recap: Akebia Therapeutics Q1 Earnings

Benzinga Insights
·1 min read

Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results.

Quarterly Results

Earnings per share fell 6.82% year over year to ($0.47), which beat the estimate of ($0.62).

Revenue of $88,478,000 up by 21.76% year over year, which beat the estimate of $77,480,000.

Looking Ahead

Akebia Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 05, 2020

View more earnings on AKBA

Time: 01:05 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/tni8ok36

Price Action

52-week high: $10.53

Company's 52-week low was at $2.99

Price action over last quarter: Up 24.78%

Company Overview

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.